249 related articles for article (PubMed ID: 8256883)
1. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
[TBL] [Abstract][Full Text] [Related]
2. Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics.
Micheletto C; Tognella S; Visconti M; Trevisan F; Dal Negro RW
Respir Med; 2006 Dec; 100(12):2144-50. PubMed ID: 16678396
[TBL] [Abstract][Full Text] [Related]
3. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
[TBL] [Abstract][Full Text] [Related]
4. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma.
Nasser SM; Patel M; Bell GS; Lee TH
Am J Respir Crit Care Med; 1995 May; 151(5):1326-30. PubMed ID: 7735581
[TBL] [Abstract][Full Text] [Related]
5. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738
[TBL] [Abstract][Full Text] [Related]
6. Urinary LTE4 is higher after nasal provocation test with L-ASA in bronchial than in only nasal responders.
Micheletto C; Visconti M; Tognella S; Trevisan F; Dal Negro RW
Eur Ann Allergy Clin Immunol; 2007 May; 39(5):162-6. PubMed ID: 17626331
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics.
Pauls JD; Simon RA; Daffern PJ; Stevenson DD
Ann Allergy Asthma Immunol; 2000 Jul; 85(1):40-5. PubMed ID: 10923603
[TBL] [Abstract][Full Text] [Related]
8. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Rubin P; Cohn J; White MV; Igarashi Y; Kaliner MA; Drazen JM
J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):1046-56. PubMed ID: 7798537
[TBL] [Abstract][Full Text] [Related]
9. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
Grissom CK; Richer LD; Elstad MR
Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
[TBL] [Abstract][Full Text] [Related]
10. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.
Sestini P; Armetti L; Gambaro G; Pieroni MG; Refini RM; Sala A; Vaghi A; Folco GC; Bianco S; Robuschi M
Am J Respir Crit Care Med; 1996 Feb; 153(2):572-5. PubMed ID: 8564100
[TBL] [Abstract][Full Text] [Related]
11. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.
Nasser SM; Bell GS; Foster S; Spruce KE; MacMillan R; Williams AJ; Lee TH; Arm JP
Thorax; 1994 Aug; 49(8):749-56. PubMed ID: 8091318
[TBL] [Abstract][Full Text] [Related]
12. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients.
Lehnigk B; Rabe KF; Dent G; Herst RS; Carpentier PJ; Magnussen H
Eur Respir J; 1998 Mar; 11(3):617-23. PubMed ID: 9596112
[TBL] [Abstract][Full Text] [Related]
13. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
Fischer AR; McFadden CA; Frantz R; Awni WM; Cohn J; Drazen JM; Israel E
Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1203-7. PubMed ID: 7551371
[TBL] [Abstract][Full Text] [Related]
14. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects.
Christie PE; Tagari P; Ford-Hutchinson AW; Charlesson S; Chee P; Arm JP; Lee TH
Am Rev Respir Dis; 1991 May; 143(5 Pt 1):1025-9. PubMed ID: 1850964
[TBL] [Abstract][Full Text] [Related]
15. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
Israel E; Cohn J; Dubé L; Drazen JM
JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
[TBL] [Abstract][Full Text] [Related]
16. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.
Christie PE; Tagari P; Ford-Hutchinson AW; Black C; Markendorf A; Schmitz-Schumann M; Lee TH
Am Rev Respir Dis; 1992 Dec; 146(6):1531-4. PubMed ID: 1333741
[TBL] [Abstract][Full Text] [Related]
17. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls.
Micheletto C; Visconti M; Tognella S; Facchini FM; Dal Negro RW
Eur Ann Allergy Clin Immunol; 2006 Jan; 38(1):20-3. PubMed ID: 16544584
[TBL] [Abstract][Full Text] [Related]
18. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
Liu MC; Dubé LM; Lancaster J
J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
[TBL] [Abstract][Full Text] [Related]
19. Urinary leukotriene E4 in bronchial asthma.
Smith CM; Hawksworth RJ; Thien FC; Christie PE; Lee TH
Eur Respir J; 1992 Jun; 5(6):693-9. PubMed ID: 1321055
[TBL] [Abstract][Full Text] [Related]
20. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma.
Nizankowska E; Bestyńska-Krypel A; Cmiel A; Szczeklik A
Eur Respir J; 2000 May; 15(5):863-9. PubMed ID: 10853850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
